This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

This study has been completed.
Eli Lilly and Company
St. Joseph's Health Care London
Information provided by:
Lawson Health Research Institute Identifier:
First received: September 14, 2006
Last updated: July 20, 2007
Last verified: July 2007
The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.

Condition Intervention Phase
Diabetes Mellitus Schizophrenia Psychotic Disorders Procedure: Management Procedure: Screening Phase 1 Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Retrospective/Prospective
Official Title: Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.

Resource links provided by NLM:

Further study details as provided by Lawson Health Research Institute:

Enrollment: 39
Study Start Date: May 2006
Study Completion Date: July 2007
  Show Detailed Description


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients active in current Regional Mental Health Care London, Specialized Adult London Ambulatory Care and Assertive Community Treatment programs with known diagnosis of a Psychotic Disorder and/or use of Novel Antipsychotics.
  • Must have family physician contact and ability to consent to medical care.

Exclusion Criteria:

  • Any patient with declaration on file stating incapable of consenting to medical treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00377117

Canada, Ontario
Regional Mental Health Care London
London, Ontario, Canada, N6A 4H1
Sponsors and Collaborators
Lawson Health Research Institute
Eli Lilly and Company
St. Joseph's Health Care London
Principal Investigator: Stewart B Harris, MD MPH CCFP FACPM Centre for Studies in Family Medicine
Principal Investigator: David RS Haslam, MSc MD FRCPC St. Joseph's Health Care London
  More Information

Publications: Identifier: NCT00377117     History of Changes
Other Study ID Numbers: R-05-470
Study First Received: September 14, 2006
Last Updated: July 20, 2007

Additional relevant MeSH terms:
Diabetes Mellitus
Psychotic Disorders
Mental Disorders
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Schizophrenia Spectrum and Other Psychotic Disorders processed this record on September 21, 2017